MeiraGTx Holdings plc reported its financial and operational results for the second quarter ended June 30, 2025. As of this date, cash, cash equivalents, and restricted cash totaled $34.4 million, compared to $101.0 million as of June 30, 2024. Service revenue for Q2 2025 was $3.7 million, an increase of $3.4 million from Q2 2024, driven by increased progress of process performance qualification services for Johnson & Johnson Innovative Medicine.
The net loss attributable to ordinary shareholders for the second quarter of 2025 was $38.8 million, or $0.48 basic and diluted net loss per ordinary share, compared to a net loss of $48.6 million, or $0.76 per share, in Q2 2024. Research and development expenses decreased by $1.4 million to $33.5 million. The company reiterated its cash runway estimate into 2027, including $17.0 million received in Q3 2025 and the remaining proceeds from the Hologen collaboration, which is expected to cover the $75.0 million debt obligation due in August 2026.
MeiraGTx provided updates on its pipeline, including gaining alignment with the FDA on the Phase 2 AQUAx2 study for AAV-hAQP1 to support a potential Biologics License Application (BLA) filing, with enrollment targeting completion by year-end 2025 and data readout in late 2026. FDG-PET data from AAV-GAD trials showed significant disease-modifying effects in pathological basal ganglia circuitry. The company plans to initiate a Phase 3 study for AAV-GAD later this year and first-in-human studies for its riboswitch platform by the end of 2025, and remains on track to file for Marketing Authorization Approval (MAA) for LCA4 in the UK and BLA in the US in the fourth quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.